Literature DB >> 6177458

Natural killer cell function in trisomy-21 (Down's syndrome).

T Nurmi, K Huttunen, O Lassila, M Henttonen, A Säkkinen, S L Linna, A Tiilikainen.   

Abstract

Natural killer (NK) activity and antibody-dependent cell mediated cytotoxicity (ADCC) against a human myeloid target cell line (K 562) was measured in adult patients with trisomy-21 (Down's syndrome) and in chromosomally normal age and sex matched control subjects. The effect of human leucocyte interferon (IFN-alpha) on the NK activity was also estimated. Spontaneous NK activity was stronger in the adult patients with trisomy-21 than in the healthy controls, but the difference did not reach statistical significance. The augmentation of NK activity by IFN-alpha, measured using lymphocytes not depleted of monocytes as effector cells, was statistically significant in both the trisomic patients (P less than 0.004) and the healthy controls (P less than 0.0005). Using monocyte and macrophage depleted lymphocytes in the patients with trisomy-21 the NK activity proved stronger than in the healthy controls, but not significantly and IFN-alpha did not augment it as it did in the healthy controls (P = n.s., P less than 0.05), for augmentations respectively). These results support the view that monocytes and macrophages are connected with the NK cell system. ADCC correlated with NK activity in both groups. Since NK cells are important components of many immune processes, including tumour and virus and/or bacteria-infected cell elimination, and have regulatory functions in immune reactions, the deficient augmentation of trisomic NK cells shown in vitro with extrinsic human leucocyte interferon may, paradoxically be an explanation for the greater susceptibility of trisomic individuals to lymphatic leukaemia and virus and bacterial infections. In vivo, this could be explained by the more potent secondary suppression by the 'immune' interferon produced by the virus, bacteria and malignant cells. In other words, the potential of the 'fighting couple' of the immune system, NK cell/interferon, is perhaps disturbed genetically due to the chromosome 21.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6177458      PMCID: PMC1536446     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

1.  Mortality and life-table in Down's syndrome.

Authors:  J Oster; M Mikkelsen; A Nielsen
Journal:  Acta Paediatr Scand       Date:  1975-03

2.  On the influence of age on immunity in Down's syndrome.

Authors:  R Seger; G Buchinger; J Ströder
Journal:  Eur J Pediatr       Date:  1977-01-26       Impact factor: 3.183

3.  A rapid method for the isolation of functional thymus-derived murine lymphocytes.

Authors:  M H Julius; E Simpson; L A Herzenberg
Journal:  Eur J Immunol       Date:  1973-10       Impact factor: 5.532

4.  Interferon inhibits DNA synthesis induced in mouse lymphocyte suspensions by phytohaemagglutinin or by allogeneic cells.

Authors:  P Lindahl-Magnusson; P Leary; I Gresser
Journal:  Nat New Biol       Date:  1972-05-24

5.  Serum levels of immune globulins in health and disease: a survey.

Authors:  E R Stiehm; H H Fudenberg
Journal:  Pediatrics       Date:  1966-05       Impact factor: 7.124

6.  "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell.

Authors:  R Kiessling; E Klein; H Pross; H Wigzell
Journal:  Eur J Immunol       Date:  1975-02       Impact factor: 5.532

7.  Derangements of immunoglobulin levels, phytohemagglutinin responsiveness and T and B cell markers in Down's syndrome at different ages.

Authors:  G R Burgio; A G Ugazio; L Nespoli; A F Marcioni; A M Bottelli; F Pasquali
Journal:  Eur J Immunol       Date:  1975-09       Impact factor: 5.532

8.  Stress deficiency of the T-lymphocyte system exemplified by Down syndrome.

Authors:  S Whittingham; D B Pitt; D L Sharma; I R Mackay
Journal:  Lancet       Date:  1977-01-22       Impact factor: 79.321

9.  T and B lymphocytes in patients with Down's syndrome.

Authors:  K Reiser; C Whitcomb; K Robinson; M R MacKenzie
Journal:  Am J Ment Defic       Date:  1976-05

10.  The linkage of genes for the human interferon-induced antiviral protein and indophenol oxidase-B traits to chromosome G-21.

Authors:  Y H Tan; J Tischfield; F H Ruddle
Journal:  J Exp Med       Date:  1973-02-01       Impact factor: 14.307

View more
  7 in total

1.  Increased activity of oligo-2',5'-adenylate synthetase in Down's syndrome and epilepsy.

Authors:  N Fujii; K Oguma; M Fujii; R Fukatsu; N Takahata; M Kitabatake
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

2.  Cell-mediated cytotoxicity in Down syndrome: impairment of allogeneic mixed lymphocyte reaction, NK and NK-like activities.

Authors:  D Montagna; R Maccario; A G Ugazio; L Nespoli; E Pedroni; P Faggiano; G R Burgio
Journal:  Eur J Pediatr       Date:  1988-10       Impact factor: 3.183

3.  Increased IFN-alpha-induced sensitivity but reduced reactivity of 2',5'-oligoadenylate synthetase (2,5AS) in trisomy 21 blood lymphocytes.

Authors:  A M Gerdes; M Hørder; V Bonnevie-Nielsen
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

4.  Lymphocyte subpopulations in Down's syndrome: high percentage of circulating HNK-1+, Leu 2a+ cells.

Authors:  R Maccario; A G Ugazio; L Nespoli; C Alberini; D Montagna; F Porta; F Bonetti; G R Burgio
Journal:  Clin Exp Immunol       Date:  1984-07       Impact factor: 4.330

5.  Antibody response to pneumococcal vaccine in patients with trisomy-21 (Down's syndrome).

Authors:  T Nurmi; M Leinonen; V M Häivä; A Tiilikainen; K Kouvalainen
Journal:  Clin Exp Immunol       Date:  1982-05       Impact factor: 4.330

6.  Altered DNA methylation in leukocytes with trisomy 21.

Authors:  Kristi Kerkel; Nicole Schupf; Kota Hatta; Deborah Pang; Martha Salas; Alexander Kratz; Mark Minden; Vundavalli Murty; Warren B Zigman; Richard P Mayeux; Edmund C Jenkins; Ali Torkamani; Nicholas J Schork; Wayne Silverman; B Anne Croy; Benjamin Tycko
Journal:  PLoS Genet       Date:  2010-11-18       Impact factor: 5.917

7.  X-ring Turner's syndrome with combined immunodeficiency and selective gonadotropin defect.

Authors:  E Donti; I Nicoletti; G Venti; P Filipponi; R Gerli; F Spinozzi; C Cernetti; P Rambotti
Journal:  J Endocrinol Invest       Date:  1989-04       Impact factor: 4.256

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.